Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Rosuvastatin and Ezetimibe in Acute Ischemic Stroke
NCT05884502Phase 4Unknown
- Sponsor
- Korea University Anam Hospital
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ezetimibe in hypercholesterolemia (2 arms), sponsored by Korea University Anam Hospital. Primary endpoint: Absolute value of low-density lipoprotein cholesterol reduction at 90 days. Status: unknown.
02
Drugs
ezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05884502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05884502.